Straits Times Index
3,330.09 +11.64 (+0.35%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
68,295.25 -1,047.88 (-1.51%) CMC Crypto 200
1,481.29 -15.17 (-1.01%)
Biocon Limited (BIOCON.NS)
| Previous close | 314.95 |
| Open | 313.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 311.00 - 320.00 |
| 52-week range | 217.50 - 331.00 |
| Volume | |
| Avg. volume | 8,636,202 |
| Market cap | 380.283B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 37.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.50 (0.16%) |
| Ex-dividend date | 04 Jul 2024 |
| 1y target est | N/A |
- PR Newswire Asia
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.
- GlobeNewswire
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India. Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India. BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed. Following the acquisitio
